Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Safety

Mifepristone

FDA Launches Large Safety Study of Mifepristone

Interim results expected as soon as July could influence whether telehealth, mail delivery, or prescriber rules for the abortion pill are tightened.

Judge Pauses Louisiana Challenge, Leaves Mail-Order Abortion Pill Policy Intact

GOP Senators Press FDA on Illegal Online Abortion Pill Sales, Launch Probe of Mifepristone Makers

Hawley Seeks Congressional Oversight of Mifepristone After FDA Offers No Timeline on Safety Review

Live Action Urges HHS and FDA to Suspend Mifepristone After Undercover Planned Parenthood Calls

Republicans Press Trump Administration to Halt Mail-Order Abortion Pills Crossing State Lines

Republicans Push to Restore In‑Person Rules for Abortion Pill at Fiery Senate Hearing

Hawley Pressures FDA Chief as Anti‑Abortion Groups Demand Firing Over Reported Mifepristone Review Delay

51 GOP Senators Press FDA and HHS to Curb Abortion Pill Access After New Generic Approval

FDA Opens Mifepristone Safety Review as 20 States Vow to Defend Access

FDA Launches New Safety Review of Abortion Pill Mifepristone

Kennedy Alleges Biden Team Skewed Abortion-Pill Data as FDA Review of Mifepristone Proceeds

FDA Commissioner Pledges Safety Review of Abortion Pill Mifepristone

HHS Orders FDA Review of Abortion Pill Following Controversial Analysis

Abortion Pill Study Fuels Debate Over Safety and Access

New Study Reveals Abortion Pill Complication Rate 22 Times Higher Than FDA Estimate

Marty Makary Faces Scrutiny in Confirmation Hearing for FDA Leadership

RFK Jr.’s HHS Nomination Faces Bipartisan Scrutiny Over Vaccine Stance and Conflicts of Interest